Click here to discover the largest collection of GeneMedi's Promise-ORF™ ORF/cDNA expression clones
- • Up to 20%-50%* off first purchase
- • Bulk quantities available
- • Citation Reward application
TECHNICAL RESOURCE
Supports
- Talk to our Expert:
[email protected]
Protocol Library Download
 |
 |
Human IL6ST/CD130/CDW130 ORF/cDNA clone-Adenovirus particle (NM_002184.4)
Cat. No.: vGMAD001601
Pre-made Human IL6ST/CD130/CDW130 Adenovirus for IL6ST overexpression in-vitro and in-vivo. The IL6ST adenoviral vector excels as a vehicle for transient gene transfection in both stable cell lines and primary cells, including DC cells, macrophages, cardiomyocytes, hepatocytes, and neurons. The purified IL6ST-encoding adenovirus also stands out as a quintessential tool for in vivo studies and vaccine research initiatives.
At GM Vector Core (GMVC), we provide bespoke adenovirus development and manufacture various grades of adenoviruses utilizing cutting-edge techniques. Dive deeper into our offerings.
Go to
gp130/IL6ST/CD130/IL6ST/CD130 products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
MSDS
Product information
| Catalog No. | Product Name | Adenovirus Grade | Adenovirus quantity |
| vGMAD001601 | Human IL6ST Adenovirus particle | Research Grade-In vitro | 1E+10PFU (1E+10pfu/ml×1ml) |
| 5E+10PFU (1E+10pfu/ml×5ml) | |||
| 1E+11PFU (1E+10pfu/ml×10ml) | |||
| Research Grade-In vivo | 1E+11PFU (1E+11pfu/ml×1ml) | ||
| GMP-like Grade | inquiry | ||
| GMP Grade | inquiry |
Product Description
| Catalog ID | vGMAD001601 |
| Gene Name | IL6ST |
| Accession Number | NM_002184.4 |
| Gene ID | 3572 |
| Species | Human |
| Product Type | Adenovirus particle (overexpression) |
| Insert Length | 2757 bp |
| Gene Alias | CD130,CDW130,GP130,HIES4,HIES4A,HIES4B,IL-6RB,IMD94,sGP130,STWS2 |
| Fluorescent Reporter | Null |
| Mammalian Cell Selection | Null |
| Fusion Tag | 3xflag (C-Terminal) |
| Promoter | CMV |
| Resistance | Kanamycin |
| ORF Nucleotide Sequence | ATGTTGACGTTGCAGACTTGGCTAGTGCAAGCCTTGTTTATTTTCCTCACCACTGAATCTACAGGTGAACTTCTAGATCCATGTGGTTATATCAGTCCTGAATCTCCAGTTGTACAACTTCATTCTAATTTCACTGCAGTTTGTGTGCTAAAGGAAAAATGTATGGATTATTTTCATGTAAATGCTAATTACATTGTCTGGAAAACAAACCATTTTACTATTCCTAAGGAGCAATATACTATCATAAACAGAACAGCATCCAGTGTCACCTTTACAGATATAGCTTCATTAAATATTCAGCTCACTTGCAACATTCTTACATTCGGACAGCTTGAACAGAATGTTTATGGAATCACAATAATTTCAGGCTTGCCTCCAGAAAAACCTAAAAATTTGAGTTGCATTGTGAACGAGGGGAAGAAAATGAGGTGTGAGTGGGATGGTGGAAGGGAAACACACTTGGAGACAAACTTCACTTTAAAATCTGAATGGGCAACACACAAGTTTGCTGATTGCAAAGCAAAACGTGACACCCCCACCTCATGCACTGTTGATTATTCTACTGTGTATTTTGTCAACATTGAAGTCTGGGTAGAAGCAGAGAATGCCCTTGGGAAGGTTACATCAGATCATATCAATTTTGATCCTGTATATAAAGTGAAGCCCAATCCGCCACATAATTTATCAGTGATCAACTCAGAGGAACTGTCTAGTATCTTAAAATTGACATGGACCAACCCAAGTATTAAGAGTGTTATAATACTAAAATATAACATTCAATATAGGACCAAAGATGCCTCAACTTGGAGCCAGATTCCTCCTGAAGACACAGCATCCACCCGATCTTCATTCACTGTCCAAGACCTTAAACCTTTTACAGAATATGTGTTTAGGATTCGCTGTATGAAGGAAGATGGTAAGGGATACTGGAGTGACTGGAGTGAAGAAGCAAGTGGGATCACCTATGAAGATAGACCATCTAAAGCACCAAGTTTCTGGTATAAAATAGATCCATCCCATACTCAAGGCTACAGAACTGTACAACTCGTGTGGAAGACATTGCCTCCTTTTGAAGCCAATGGAAAAATCTTGGATTATGAAGTGACTCTCACAAGATGGAAATCACATTTACAAAATTACACAGTTAATGCCACAAAACTGACAGTAAATCTCACAAATGATCGCTATCTAGCAACCCTAACAGTAAGAAATCTTGTTGGCAAATCAGATGCAGCTGTTTTAACTATCCCTGCCTGTGACTTTCAAGCTACTCACCCTGTAATGGATCTTAAAGCATTCCCCAAAGATAACATGCTTTGGGTGGAATGGACTACTCCAAGGGAATCTGTAAAGAAATATATACTTGAGTGGTGTGTGTTATCAGATAAAGCACCCTGTATCACAGACTGGCAACAAGAAGATGGTACCGTGCATCGCACCTATTTAAGAGGGAACTTAGCAGAGAGCAAATGCTATTTGATAACAGTTACTCCAGTATATGCTGATGGACCAGGAAGCCCTGAATCCATAAAGGCATACCTTAAACAAGCTCCACCTTCCAAAGGACCTACTGTTCGGACAAAAAAAGTAGGGAAAAACGAAGCTGTCTTAGAGTGGGACCAACTTCCTGTTGATGTTCAGAATGGATTTATCAGAAATTATACTATATTTTATAGAACCATCATTGGAAATGAAACTGCTGTGAATGTGGATTCTTCCCACACAGAATATACATTGTCCTCTTTGACTAGTGACACATTGTACATGGTACGAATGGCAGCATACACAGATGAAGGTGGGAAGGATGGTCCAGAATTCACTTTTACTACCCCAAAGTTTGCTCAAGGAGAAATTGAAGCCATAGTCGTGCCTGTTTGCTTAGCATTCCTATTGACAACTCTTCTGGGAGTGCTGTTCTGCTTTAATAAGCGAGACCTAATTAAAAAACACATCTGGCCTAATGTTCCAGATCCTTCAAAGAGTCATATTGCCCAGTGGTCACCTCACACTCCTCCAAGGCACAATTTTAATTCAAAAGATCAAATGTATTCAGATGGCAATTTCACTGATGTAAGTGTTGTGGAAATAGAAGCAAATGACAAAAAGCCTTTTCCAGAAGATCTGAAATCATTGGACCTGTTCAAAAAGGAAAAAATTAATACTGAAGGACACAGCAGTGGTATTGGGGGGTCTTCATGCATGTCATCTTCTAGGCCAAGCATTTCTAGCAGTGATGAAAATGAATCTTCACAAAACACTTCGAGCACTGTCCAGTATTCTACCGTGGTACACAGTGGCTACAGACACCAAGTTCCGTCAGTCCAAGTCTTCTCAAGATCCGAGTCTACCCAGCCCTTGTTAGATTCAGAGGAGCGGCCAGAAGATCTACAATTAGTAGATCATGTAGATGGCGGTGATGGTATTTTGCCCAGGCAACAGTACTTCAAACAGAACTGCAGTCAGCATGAATCCAGTCCAGATATTTCACATTTTGAAAGGTCAAAGCAAGTTTCATCAGTCAATGAGGAAGATTTTGTTAGACTTAAACAGCAGATTTCAGATCATATTTCACAATCCTGTGGATCTGGGCAAATGAAAATGTTTCAGGAAGTTTCTGCAGCAGATGCTTTTGGTCCAGGTACTGAGGGACAAGTAGAAAGATTTGAAACAGTTGGCATGGAGGCTGCGACTGATGAAGGCATGCCTAAAAGTTACTTACCACAGACTGTACGGCAAGGCGGCTACATGCCTCAGTGA |
| ORF Protein Sequence | MLTLQTWLVQALFIFLTTESTGELLDPCGYISPESPVVQLHSNFTAVCVLKEKCMDYFHVNANYIVWKTNHFTIPKEQYTIINRTASSVTFTDIASLNIQLTCNILTFGQLEQNVYGITIISGLPPEKPKNLSCIVNEGKKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDTPTSCTVDYSTVYFVNIEVWVEAENALGKVTSDHINFDPVYKVKPNPPHNLSVINSEELSSILKLTWTNPSIKSVIILKYNIQYRTKDASTWSQIPPEDTASTRSSFTVQDLKPFTEYVFRIRCMKEDGKGYWSDWSEEASGITYEDRPSKAPSFWYKIDPSHTQGYRTVQLVWKTLPPFEANGKILDYEVTLTRWKSHLQNYTVNATKLTVNLTNDRYLATLTVRNLVGKSDAAVLTIPACDFQATHPVMDLKAFPKDNMLWVEWTTPRESVKKYILEWCVLSDKAPCITDWQQEDGTVHRTYLRGNLAESKCYLITVTPVYADGPGSPESIKAYLKQAPPSKGPTVRTKKVGKNEAVLEWDQLPVDVQNGFIRNYTIFYRTIIGNETAVNVDSSHTEYTLSSLTSDTLYMVRMAAYTDEGGKDGPEFTFTTPKFAQGEIEAIVVPVCLAFLLTTLLGVLFCFNKRDLIKKHIWPNVPDPSKSHIAQWSPHTPPRHNFNSKDQMYSDGNFTDVSVVEIEANDKKPFPEDLKSLDLFKKEKINTEGHSSGIGGSSCMSSSRPSISSSDENESSQNTSSTVQYSTVVHSGYRHQVPSVQVFSRSESTQPLLDSEERPEDLQLVDHVDGGDGILPRQQYFKQNCSQHESSPDISHFERSKQVSSVNEEDFVRLKQQISDHISQSCGSGQMKMFQEVSAADAFGPGTEGQVERFETVGMEAATDEGMPKSYLPQTVRQGGYMPQ |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Target Antibody | GM-Tg-g-TA093-Ab | Anti-IL6RB/ IL6ST/ CD130 monoclonal antibody |
| Target Antigen | GM-Tg-g-TA093-Ag | IL6ST VLP (virus-like particle) |
| Cytokine | cks-Tg-g-GM-TA093 | interleukin 6 signal transducer (IL6ST) protein & antibody |
| ORF Viral Vector | pGMAD001601 | Human IL6ST Adenovirus plasmid |
| ORF Viral Vector | vGMAD001601 | Human IL6ST Adenovirus particle |
Target information
| Target ID | GM-TA093 |
| Target Name | gp130/IL6ST/CD130 |
|
Gene Group Identifier （Target Gene ID in Homo species) |
3572 |
| Gene ID |
100051700 (Equus caballus), 101089832 (Felis catus), 16195 (Mus musculus), 25205 (Rattus norvegicus) 3572 (Homo sapiens), 403545 (Canis lupus familiaris), 522155 (Bos taurus), 574127 (Macaca mulatta) |
| Gene Symbols & Synonyms | IL6ST,Il6st,CD130,gp130,D13Ertd699e,5133400A03Rik,Gp130,Ac1055,Il-6rb,GP130,HIES4,IMD94,STWS2,CDW130,HIES4A,HIES4B,IL-6RB,sGP130,IL-6 |
| Target Alternative Names | 5133400A03Rik,Ac1055,CD130,CDW130,CDw130,D13Ertd699e,GP130,Gp130,HIES4,HIES4A,HIES4B,IL-6,IL-6 receptor subunit beta,IL-6R subunit beta,IL-6R-beta,IL-6RB,IL6ST,IMD94,Il-6rb,Il6st,Interleukin-6 receptor subunit beta,Interleukin-6 signal transducer,Membrane glycoprotein 130 (gp130),Oncostatin-M receptor subunit alpha,STWS2,gp130,sGP130 |
| Uniprot Accession |
P40189,P40190,Q00560
Additional SwissProt Accessions: Q00560,P40190,P40189 |
| Uniprot Entry Name | |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Immuno-oncology Target, Cytokine Target |
| Disease | cancer, Mucocutaneous lymph node syndrome [Kawasaki], breast cancer |
| Disease from KEGG | Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Signaling pathways regulating pluripotency of stem cells, JAK-STAT signaling pathway, Th17 cell differentiation, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer |
| Gene Ensembl | ENSECAG00000019750, ENSMUSG00000021756, ENSG00000134352, ENSCAFG00845028368, ENSBTAG00000017745, ENSMMUG00000001893 |
| Target Classification | Cytokine Receptor, Checkpoint-Immuno Oncology |
About GMVC
GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.